AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Arcturus Therapeutics RSI Overbought, KDJ Death Cross Triggered on 15min Chart
ByAinvest
Thursday, Aug 7, 2025 10:02 am ET1min read
As of August 7th, 2025 at 9:45am, Arcturus Therapeutics's 15-minute chart has reached an RSI Overbought status, accompanied by a KDJ Death Cross. This indicates that the stock price has experienced a rapid increase, exceeding the fundamental support, and its momentum is shifting towards a downward trend, with potential for further depreciation.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a late-stage clinical messenger RNA medicines and vaccine company, is expected to report a significant decrease in quarterly revenue when it releases its financial results on August 4, 2025 [1]. Analysts predict a 55.0% fall in revenue to $22.435 million from $49.86 million a year ago, with a mean estimate of a 90 cents per share loss [1].The current consensus among analysts is overwhelmingly positive, with 12 "strong buy" or "buy" ratings and no "hold," "sell," or "strong sell" ratings. The mean earnings estimate from analysts has remained unchanged over the past three months, and the median 12-month price target stands at $48.00, about 74.6% above the last closing price of $12.21 [1].
Technical indicators, however, suggest a potential market correction. As of August 7th, 2025 at 9:45am, Arcturus Therapeutics' 15-minute chart has reached an RSI Overbought status, accompanied by a KDJ Death Cross. This indicates that the stock price has experienced a rapid increase, exceeding fundamental support, and its momentum is shifting towards a downward trend, with potential for further depreciation [2].
Several hedge funds have recently increased their stakes in Arcturus Therapeutics, reflecting positive institutional sentiment. Byrne Asset Management LLC, US Bancorp DE, Virtus ETF Advisers LLC, KLP Kapitalforvaltning AS, and Strs Ohio have all increased their holdings in the company [2].
Despite the positive sentiment from analysts and institutional investors, the technical indicators suggest caution. Investors should closely monitor the company's earnings report and market trends to make informed decisions.
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TT2R6:0-arcturus-therapeutics-holdings-inc-expected-to-post-a-loss-of-90-cents-a-share-earnings-preview/
[2] https://www.marketbeat.com/instant-alerts/arcturus-therapeutics-holdings-inc-nasdaqarct-given-average-recommendation-of-buy-by-brokerages-2025-08-07/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet